series-a
Stage
2019
Founded
1
Investors
About
Lentitek develops manufacturing technologies for lentiviral vectors, which are essential in the delivery of CAR-T cell and gene therapies. This improves the production yield of viral vectors used in gene therapies and gene-modified cell therapies, making advanced cancer therapies more widely accessible.
Explore Lentitek's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.